Latest News

SandboxAQ, Bahrain's sovereign funds, signs deal with AI to speed up drug development

SandboxAQ - a U.S. artificial intelligence and quantum tech firm - signed an agreement on Monday with Bahrain's sovereign fund to speed up the development and creation of biotech assets valued at $1 billion.

Mumtalakat, Bahrain, will license SandboxAQ’s large, quantitative models that are trained in physics, chemistry, and biology, to speed up drug discovery and scientific investigation. The deal was announced at the Future Investment Initiative, Saudi Arabia's premier investment conference.

The statement said that the collaboration would help to position Bahrain as a regional hub for biotech, with a joint committee leading a program of three years aimed at creating valuable new drugs.

SandboxAQ CEO Jack Hidary said the partnership will empower Bahrain to create, own and use intellectual property (IP) in biotech. This includes therapies that target diseases common in the region like diabetes and genetic disorders.

"Traditionally, most biotech IP belongs to a few countries. Hidary explained that Bahrain can now develop its own assets focusing on both regional and global priorities in health.

Bahrain's hospital infrastructure and digital health datasets will be used to develop treatments under the agreement. Hidary said that clinical trials will begin in Bahrain with the potential of multi-site studies.

SandboxAQ is also receiving interest for similar partnerships from other countries including the Gulf.

Aramco, the Saudi oil giant, signed an agreement in January with SandboxAQ that would allow it to use their models to boost the value of its downstream products. Mark Potter edited the report by Yousef Sabah.

(source: Reuters)